Search

Background: There is a need to better understand the experience of patients living with Alzheimer's disease (AD) in the early stages.Objective: The aim of the study was to evaluate the perception of quality of life in patients with early-stage AD.Methods: A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD, a Mini-Mental State Examination (MMSE) score ≥22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5.-1.0. The Quality of Life in Alzheimer 's Disease (QoL-AD) questionnaire was used to assess health-related quality of life. A battery of self-report instruments was used to evaluate different psychological and behavioral domains. Associations between the QoL-AD and other outcome measures were analyzed using Spearman's rank correlations.Results: A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years and mean disease duration was 1.4 (1.8) years. Mean MMSE score was 24.6 (2.1). The mean QoL-AD score was 37.9 (4.5). Eighty-three percent (n = 124) of patients had moderate-to-severe hopelessness, 22.1% (n = 33) had depressive symptoms, and 36.9% (n = 55) felt stigmatized. The quality of life showed a significant positive correlation with self-efficacy and negative correlations with depression, emotional and practical consequences, stigma, and hopelessness.Conclusion: Stigma, depressive symptoms, and hopelessness are frequent scenarios in AD negatively impacting quality of life, even in a population with short disease duration and minimal cognitive impairment. [ABSTRACT FROM AUTHOR]

Background: Limited information is available on the active process of seeking medical help in patients with Alzheimer's disease (AD) at early stages. The aim of this study was to assess the phenomenon of medical help-seeking in early AD and to identify associated factors., Methods: A multicenter, non-interventional study was conducted including patients of 50-90 years of age with prodromal or mild AD (National Institute on Aging/Alzheimer's Association criteria), a Mini-Mental State Examination (MMSE) score ≥ 22, and a Clinical Dementia Rating-Global score (CDR-GS) of 0.5-1.0. A multivariate logistic regression analysis was conducted., Results: A total of 149 patients were included. Mean age (SD) was 72.3 (7.0) years, 50.3% were female, and 87.2% had a CDR-GS score of 0.5. Mean disease duration was 1.4 (1.8) years. Ninety-four (63.1%) patients sought medical help, mostly from neurologists. Patients with help-seeking intentions were mostly female (60.6%) with a CDR-GS score of 0.5 (91.5%) and had a greater awareness of diagnosis, poorer quality of life, more depressive symptoms, and a more severe perception of their condition than their counterparts. Lack of help-seeking intentions was associated with male sex ( p  = 0.003), fewer years of education ( p  = 0.005), a low awareness of diagnosis ( p  = 0.005), and a low emotional consequence of the condition ( p  = 0.016)., Conclusion: Understanding the phenomenon of active medical help-seeking may facilitate the design of specific strategies to improve the detection of cognitive impairment, especially in patients with a lower level of educational attainment and poor awareness of their condition., Competing Interests: EG-A and JM are employees of Roche Farma Spain. AV-G discloses honoraria from a consulting/advisory role with KRKA, Kern Pharma, Exeltis, Esteve, Roche, AbbVie, Schwabe, Neuraxpharm, Nutricia, and Alter. AO-R discloses honoraria from a consulting/advisory role with Alter, Biocross, Biogen, KRKA, Esteve, Schwabe, Nutricia, and Lilly. EF-M discloses honoraria from a consulting/advisory role with Kern Pharma, Esteve, Roche, and Neuraxpharm. MeB discloses honoraria from a consulting/advisory role with Grifols, Araclon Biotech, Roche, Lilly, Merck, Biogen, Zambon, Novo-Nordisk, Bioiberica, Biogen, Eisai, Servier, and Schwabe Pharma. RA discloses their participation on an advisory board and having received speaking fees from Almirall, Bayer, Biogen, Merck, Novartis, Roche, Sanofi, and Teva. AL discloses honoraria from a consulting/advisory role with Grifols, Fujirebio-Europe, Novartis, Roche, Otsuka, Nutricia, Zambón, Biogen, Lilly, and KRKA. A preliminary report of this data was presented as an eposter at the 9th Congress of the European Academy of Neurology (EPO-187, Budapest, Hungary; July 1–4, 2023). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Villarejo-Galende, García-Arcelay, Piñol-Ripoll, del Olmo-Rodríguez, Viñuela, Boada, Franco-Macías, Ibañez de la Peña, Riverol, Puig-Pijoan, Abizanda-Soler, Arroyo, Baquero-Toledo, Feria-Vilar, Balasa, Berbel, Rodríguez-Rodríguez, Vieira-Campos, Garcia-Ribas, Rodrigo-Herrero, Lleó and Maurino.)